P62 Cost-Effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib in the Treatment of BRAF V600 Mutation-Positive Metastatic Melanoma
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.080
https://www.valueinhealthjournal.com/article/S1098-3015(22)00281-9/fulltext
Title :
P62 Cost-Effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib in the Treatment of BRAF V600 Mutation-Positive Metastatic Melanoma
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00281-9&doi=10.1016/j.jval.2022.04.080
First page :
Section Title :
Open access? :
No
Section Order :
10063